Latest Articles
-
CVS’ Q2 Earnings Might Be Dampened By Its Retail/LTC Segment On Account Of Its Contract Losses To Walgreen
CVS Health (NYSE:CVS) is scheduled to announce its second quarter results on August 8th. The company witnessed a rough 2016 by losing contracts with the Department of Defense and Prime Therapeutics to its rival Walgreens. The new deals came into...
-
CVS Q1 Earnings Review: Contract Losses Hurt Bottom Line
CVS (NYSE:CVS) announced disappointing first quarter earnings on May 2. The company’s performance was impacted by lost contracts with the Department of Defense and Prime Therapeutics to its rival Walgreens. The new deals came into effect i...
-
CVS Earnings Preview: Contract Losses Likely To Impact Results
CVS Health (NYSE:CVS) is scheduled to announce its first quarter results on May 2. The company is coming off a turbulent 2016, in which it lost contracts with the Department of Defense and Prime Therapeutics to its rival Walgreens. The new deals...
-
Key Takeaways From CVS’ Earnings
CVS (NYSE:CVS) announced its Q4 and full year earnings on Thursday, February 9. In the quarter ended December 31st, the company’s revenue grew by 12% year-on-year (y-o-y) to $46 billion for the quarter, primarily on the basis of the strong...
-
CVS Q4 Earnings: What To Expect
CVS Health (NYSE:CVS) is slated to announce its fourth quarter and full year results on Thursday, February 9th before the markets open. We expect the company to see an uptick in revenues – aided by strong volumes and growth in Medicare Par...
-
What Is The Potential Of CVS’s EpiPen Substitute?
Last week, CVS Health (NYSE:CVS) announced the launch of a cheaper generic alternative to Mylan’s EpiPen. The cheaper alternative low-cost epinephrine injector, manufactured by Impax Laboratories, is an approved generic for Adrenaclick an...
-
Pharmacy Services Continue To Drive CVS’s Growth
CVS (NYSE:CVS) announced its Q3 earnings on Tuesday, November 8th. In the quarter ended September 30th, the company’s revenue grew by 15.4% year-on-year (y-o-y) to $44.6 billion for the quarter. Despite the growth, the company missed the c...
-
CVS Q3 Earnings: What To Expect?
CVS Health (NYSE:CVS) is slated to announce its third quarter results on Tuesday, November 8th before the markets open. In the current quarter, we expect the company to show an uptick in revenues – aided by strong volumes and growth in Med...
-
Why Pharmacy Services Will Drive CVS’ Growth Going Forward
CVS (NYSE:CVS), the market leader in the retail pharmacy sector, has consistently strengthened its offerings in recent years, particularly with its acquisition of Omnicare and Target’s pharmacy division. The acquisition of Omnicare has he...
-
CVS Earnings Review: Integration Costs Take Toll On Margins
CVS (NYSE:CVS) announced its Q2 earnings on Tuesday, August 2nd. In the quarter ended June 30th, the company’s revenue grew by 17.6% year-on-year (y-o-y) to $43.7 billion for the quarter. Despite the growth, the revenue figures actually mi...
-
Walgreens-Rite Aid Merger: How Will The Combined Entity Compare With CVS?
Last year, Walgreens (NASDAQ:WBA) announced its plans to acquire Rite Aid (NYSE: RAD) in a deal worth $17.2 billion. After the completion of the deal, which is expected to close in the second half of 2016, Rite Aid will be a wholly owned subsi...
-
CVS Q1 Earnings Review : Revenues, EPS Increase
CVS (NYSE:CVS) announced its Q1 earnings on Tuesday, May 3rd. The company’s revenue grew by 18.9% year-on-year (y-o-y) to $43.2 billion for the quarter. The rise in revenue was primarily driven by the strong performance of the PBM business...
-
What to Expect from CVS Q1Earnings
CVS Health (NYSE:CVS) is set to announce its Q1 earnings on Tuesday, May 3rd. The year 2015 was a good one for CVS, with earnings in line with consensus estimates. In fiscal year 2015, the company’s revenue was $153.3 billion (up 10% from ...
-
By How Much Can CVS’s Revenue & EBITDA Grow In The Next 5 Years: Trefis Estimate
Revenue CAGR: ~5% [Most of the growth is expected from Pharmacy Services Business] EBITDA CAGR: ~5% Have more questions about CVS Health (NYSE:CVS)? Click on the links below: What is CVS’s Current Revenue & EBITDA Break...
-
By What Percentage Did CVS’s Revenue & EBITDA Grow In The Last 5 Years?
Revenue Growth: ~10% CAGR [Growth driven primarily by increase in Pharmacy Services (PBM) Revenue] EBITDA Growth: <10% CAGR [ Growth driven by an increase in Prescription Drugs & Pharmacy Services EBITDA] Have more questions about CVS ...
